# Assessment of Survival and Autonomy With Rituximab Plus Chemotherapy or Rituximab Plus Lenalidomide for Elderly Patients With Relapsed Diffuse Large B-cell Lymphoma

> **NCT04113226** · PHASE2 · UNKNOWN · sponsor: **Centre Hospitalier Universitaire, Amiens** · enrollment: 114 (estimated)

## Conditions studied

- Chemotherapy
- Diffuse Large B-Cell Lymphoma (DLBCL), Nos
- Elderly

## Interventions

- **DRUG:** Rituximab
- **DRUG:** Lenalidomide 20 MG
- **OTHER:** Comprehensive Geriatric Assessment (CGA)
- **OTHER:** Activities of daily living (ADL) scale

## Key facts

- **NCT ID:** NCT04113226
- **Lead sponsor:** Centre Hospitalier Universitaire, Amiens
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-07-26
- **Primary completion:** 2024-12
- **Final completion:** 2024-12
- **Target enrollment:** 114 (ESTIMATED)
- **Last updated:** 2023-02-08

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04113226

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04113226, "Assessment of Survival and Autonomy With Rituximab Plus Chemotherapy or Rituximab Plus Lenalidomide for Elderly Patients With Relapsed Diffuse Large B-cell Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04113226. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*